David Muccino, M.D.

David Muccino is a physician clinical researcher with broad experience in pharmaceutical drug development and medical affairs. Dr. Muccino majored in molecular biology and biochemistry at Rutgers University and attended medical school at UMDNJ. He completed his internal medicine residency at Thomas Jefferson University and attended pulmonary and critical care fellowship training at NYU. Subsequently, Dr. Muccino joined the consulting firm Easton Associates (now Navigant) where he advised multiple pharmaceutical and device companies regarding their clinical development plans. Then Dr. Muccino joined Bayer as an associate director in medical affairs where he was responsible for overseeing successful completion of two Phase III trials for Adempas and providing strategic direction and medical review for the NDA. He was the U.S. medical lead role in addressing FDA questions during NDA submission and label discussions leading to successful approval of Adempas. Dr. Muccino joined Merck in 2015 in a clinical development role and was responsible for the phase 3 chronic cough program for MK-7264 for gefapixant. David worked for GSK for the last 4 and a half years where he worked in asthma, RCC, and PH.